Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNP023 versus anti-C5 standard therapy in adults with PNH and residual anemia
NL-OMON51938Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Iptacopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Novartis. Started Jan 2021; status: active, not recruiting.
02
Drugs
Iptacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NL-OMON51938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51938.